弥漫性大B细胞淋巴瘤诊断时外周血淋巴细胞/单核细胞比值的预后作用：一项荟萃分析
Prognostic role of peripheral blood lymphocyte/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis.
作者信息
Lin Baochai, Chen Cuie, Qian Yan, Feng Jianhua
机构信息
a Division of Radiation Oncology and Chemotherapy, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , P. R. China.
b Division of Pediatrics, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , P. R. China.
出版信息
Leuk Lymphoma. 2015;56(9):2563-8. doi: 10.3109/10428194.2015.1014367. Epub 2015 Mar 3.
To evaluate the prognostic value of the absolute lymphocyte count/absolute monocyte count ratio (ALC/AMC ratio) at diagnosis in diffuse large B-cell lymphoma (DLBCL), we performed a meta-analysis of published studies that provided survival information with reference to the ALC/AMC ratio at diagnosis. Nine studies covering a total of 4198 subjects were included in this analysis. The summary hazard ratios of low ALC/AMC ratio for overall survival were 2.00 (p = 0.000) in the population that received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and 1.12 (p = 0.479) in the population that received CHOP. The corresponding ratios for event-free survival and progression-free survival were 1.93 (p = 0.000) and 2.31 (p = 0.000) in the population that received R-CHOP. These results may justify risk-adapted therapeutic strategies for patients with DLBCL treated with R-CHOP to account for the ALC/AMC ratio at diagnosis.
为评估弥漫性大B细胞淋巴瘤（DLBCL）诊断时绝对淋巴细胞计数/绝对单核细胞计数比值（ALC/AMC比值）的预后价值，我们对已发表的研究进行了一项荟萃分析，这些研究提供了与诊断时ALC/AMC比值相关的生存信息。本分析纳入了9项研究，共4198名受试者。接受R-CHOP（利妥昔单抗、环磷酰胺、阿霉素、长春新碱、泼尼松）治疗的人群中，低ALC/AMC比值对总生存的汇总风险比为2.00（p = 0.000），接受CHOP治疗的人群中为1.12（p = 0.479）。接受R-CHOP治疗的人群中，无事件生存和无进展生存的相应比值分别为1.93（p = 0.000）和2.31（p = 0.000）。这些结果可能为接受R-CHOP治疗的DLBCL患者根据诊断时的ALC/AMC比值采取风险适应性治疗策略提供依据。
Zotero 插件